ALKEM Alkem Lab Q3 FY25 results (Oct–Dec 2024) and concall
Alkem Lab reported a resilient Q3 FY25 with modest revenue growth and strong EBITDA margin expansion, driven by improved profitability actions and domestic market performance. The company is strategically expanding its portfolio through acquisitions and preparing for key product launches like GLP-1 in India. While facing challenges in the US market due to price erosion and specific non-US markets like Chile, management remains confident in achieving its full-year EBITDA margin guidance and future growth drivers.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 3,415 | 3,374 |
| EBITDA | 753 | 759 |
| Net profit | 702 | 641 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
